Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goki Suda

Showing results (91-100 of 148) with videos related to

Pageof 15
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2022
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver diseaseAkihisa Nakamura, Koji Yamamoto, Rei Takeda, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2024
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosisShusuke Kumazaki, Hayato Hikita, Yuki Tahata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 12, 2014
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsGoki Suda, Yoshiya Yamamoto, Astushi Nagasaka, et al.
Journal of Gastroenterology|January 16, 2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CGoki Suda, Mineo Kudo, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 13, 2016
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairmentGoki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2018
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunctionTakuya Sho, Goki Suda, Atsushi Nagasaka, et al.
Hepatology Communications|June 3, 2024
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLDSadatsugu Sakane, Hayato Hikita, Kumiko Shirai, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patientsMachiko Umemura, Koji Ogawa, Kenichi Morikawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Scientific Reports|October 7, 2022
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapyNaoki Kawagishi, Goki Suda, Ryotaro Sakamori, et al.
Pageof 15

Showing results (91-100 of 148) with videos related to

Sort By:
Pageof 15
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 7, 2022
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver diseaseAkihisa Nakamura, Koji Yamamoto, Rei Takeda, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2024
Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosisShusuke Kumazaki, Hayato Hikita, Yuki Tahata, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 12, 2014
Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactionsGoki Suda, Yoshiya Yamamoto, Astushi Nagasaka, et al.
Journal of Gastroenterology|January 16, 2016
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis CGoki Suda, Mineo Kudo, Atsushi Nagasaka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 13, 2016
Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairmentGoki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 10, 2018
Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunctionTakuya Sho, Goki Suda, Atsushi Nagasaka, et al.
Hepatology Communications|June 3, 2024
Proteomic analysis of serum extracellular vesicles reveals Fibulin-3 as a new marker predicting liver-related events in MASLDSadatsugu Sakane, Hayato Hikita, Kumiko Shirai, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 30, 2022
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patientsMachiko Umemura, Koji Ogawa, Kenichi Morikawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 21, 2020
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteriaTakuya Sho, Goki Suda, Koji Ogawa, et al.
Scientific Reports|October 7, 2022
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapyNaoki Kawagishi, Goki Suda, Ryotaro Sakamori, et al.
Pageof 15